Celcuity的乳腺癌药物显示,在预防疾病发展、库存激增方面,76%的改善。 Celcuity's breast cancer drug shows 76% improvement in preventing disease progression, stock surges.

Celcuity第3阶段对高乳癌的gedatolisib试验显示,在无进展存活方面有显著改善,比目前的治疗减少了76%的疾病发病风险。 Celcuity's Phase 3 trial for gedatolisib in advanced breast cancer showed significant improvement in progression-free survival, reducing the risk of disease progression by 76% compared to current treatments. 治疗三组治疗的中位生存时间为9. 3个月,治疗两组治疗的中位生存时间为7. 4个月,与单独使用富尔韦斯坦的中位生存时间为2. 0个月相比. The median survival time was 9.3 months with the triplet therapy and 7.4 months with the doublet therapy, compared to 2.0 months with fulvestrant alone. 凯尔科计划在2025年第四季度向FDA提交申请,其股票在市场前交易中升了100%. Celcuity plans to file an application with the FDA in Q4 2025, and its stock surged over 100% in pre-market trading.